The tumor-suppressor miRNA-126 (miR-126) is decreased in human breast and pancreatic cancers, resulting in increased pro-metastatic KRAS (Kirsten rat sarcoma viral oncogene homologue) levels 49-51. Here, KRAS is linked to neoplasm.